Regeneron Pharmaceuticals, Inc.
Modifying binding molecules to minimize pre-exisiting interactions

Abstract:

The present disclosure is directed towards modifying binding molecules in order to minimize pre-existing binding interactions, including binding molecules engineered to minimize or mitigate background reactivity in a sample matrix caused by drug non-specific binding interactions.